Singapore, June 29 -- Japan-based Nippon Shinyaku has entered into an option agreement with US-based Elixirgen Therapeutics, Inc. under which Nippon Shinyaku may obtain the exclusive worldwide rights to develop and commercialise EXG-7001 for the treatment of Duchenne muscular dystrophy (DMD).

The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.

Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder causing muscle weakness due to the absence or dysfunction of dystrophin.

"Collaboration is essential in furthering scientific innovation, and we are proud to partner with Elixirgen to expand treatment options for the Duchenne community," said NS Pharma Presid...